相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin
S. L. Stocker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment A 1-year, randomized, double-blind, placebo-controlled study
Janet B. McGill et al.
DIABETES CARE (2013)
Efficacy and safety of Jentadueto® (linagliptin plus metformin)
Andre J. Scheen
EXPERT OPINION ON DRUG SAFETY (2013)
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers
Sreeraj Macha et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Metformin in patients with chronic kidney disease: strengths and weaknesses
Ana Rocha et al.
JOURNAL OF NEPHROLOGY (2013)
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
Valentina Lukashevich et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2013)
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update Foreword
Michael V. Rocco et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2012)
Management of Hyperglycemia, Dyslipidemia, and Albuminuria in Patients With Diabetes and CKD: A Systematic Review for a KDOQI Clinical Practice Guideline
Yelena Slinin et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2012)
Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
Yan-Ling He
CLINICAL PHARMACOKINETICS (2012)
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Larry K. Golightly et al.
CLINICAL PHARMACOKINETICS (2012)
Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes
B. Detournay et al.
DIABETES & METABOLISM (2012)
A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency
David Baldwin et al.
DIABETES CARE (2012)
One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
W. Kothny et al.
DIABETES OBESITY & METABOLISM (2012)
Metformin therapy in patients with chronic kidney disease
J. K. Duong et al.
DIABETES OBESITY & METABOLISM (2012)
Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis
M. Pendergrass et al.
DIABETES OBESITY & METABOLISM (2012)
Outcomes and lessons from the PROactive study
Andre J. Scheen
DIABETES RESEARCH AND CLINICAL PRACTICE (2012)
Metformin-associated lactic acidosis following acute kidney injury. Efficacious treatment with continuous renal replacement therapy
S. Dichtwald et al.
DIABETIC MEDICINE (2012)
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. E. Inzucchi et al.
DIABETOLOGIA (2012)
Dapagliflozin A Review of its Use in Type 2 Diabetes Mellitus
Greg L. Plosker
DRUGS (2012)
Repaglinide A Review of Its Use in Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2012)
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Drug-induced hypoglycaemia in type 2 diabetes
Berit Inkster et al.
EXPERT OPINION ON DRUG SAFETY (2012)
A review of gliptins in 2011
Andre J. Scheen
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Evaluation of Modification of Diet in Renal Disease study and Cockcroft-Gault equations for sitagliptiin dosing
M. Shawn McFarland et al.
JOURNAL OF NEPHROLOGY (2012)
Characteristics of Patients With Sulphonurea-Induced Hypoglycemia
Yael Dinur Schejter et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2012)
Comparative effectiveness of incident oral antidiabetic drugs on kidney function
Adriana M. Hung et al.
KIDNEY INTERNATIONAL (2012)
Liraglutide-Induced Acute Kidney Injury
Yaman Kaakeh et al.
PHARMACOTHERAPY (2012)
Use of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Nasser Mikhail
POSTGRADUATE MEDICINE (2012)
Intervention to Decrease Glyburide Use in Elderly Patients With Renal Insufficiency
Sherrie L. Aspinall et al.
AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY (2011)
Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
David W. Boulton et al.
CLINICAL PHARMACOKINETICS (2011)
Clinical Pharmacokinetics of Metformin
Garry G. Graham et al.
CLINICAL PHARMACOKINETICS (2011)
Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice
Masanori Abe et al.
CURRENT DRUG METABOLISM (2011)
Inherited Variation in Vitamin D Genes Is Associated With Predisposition to Autoimmune Disease Type 1 Diabetes
Jason D. Cooper et al.
DIABETES (2011)
Estimation of renal function in patients with diabetes
V. Rigalleau et al.
DIABETES & METABOLISM (2011)
Limitations and Future Treatment Options in Type 2 Diabetes With Renal Impairment
Eberhard Ritz
DIABETES CARE (2011)
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Kasia J. Lipska et al.
DIABETES CARE (2011)
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin
U. Graefe-Mody et al.
DIABETES OBESITY & METABOLISM (2011)
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
M. Nowicki et al.
DIABETES OBESITY & METABOLISM (2011)
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
V. Lukashevich et al.
DIABETES OBESITY & METABOLISM (2011)
Thiazolidinediones and fracture risk in patients with Type 2 diabetes
D. J. Betteridge
DIABETIC MEDICINE (2011)
The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
Midori Ito et al.
ENDOCRINE JOURNAL (2011)
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
The safety of thiazolidinediones
Keith G. Tolman
EXPERT OPINION ON DRUG SAFETY (2011)
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
M. Nowicki et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States
Ian H. de Boer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study
Matthew A. Weir et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?
Helen J. Nye et al.
NEPHRON CLINICAL PRACTICE (2011)
Type 2 Diabetes Mellitus and Renal Impairment in a Large Outpatient Electronic Medical Records Database: Rates of Diagnosis and Antihyperglycemic Medication Dose Adjustment
Juliana L. Meyers et al.
POSTGRADUATE MEDICINE (2011)
Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus
Candis M. Morello
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2011)
Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis
Ronan Roussel et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Novel Assay of Metformin Levels in Patients With Type 2 Diabetes and Varying Levels of Renal Function Clinical recommendations
Anders Frid et al.
DIABETES CARE (2010)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
Limitations of metformin use in patients with kidney disease: are they warranted?
K. P. Vasisht et al.
DIABETES OBESITY & METABOLISM (2010)
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
M. Ligueros-Saylan et al.
DIABETES OBESITY & METABOLISM (2010)
Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study
M. A. Banerji et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Lactic Acidosis Induced by Metformin Incidence, Management and Prevention
Jean-Daniel Lalau
DRUG SAFETY (2010)
Sodium-Glucose Co-Transport Inhibitors Progress and Therapeutic Potential in Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
DRUGS (2010)
Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis
Masanori Abe et al.
ENDOCRINE JOURNAL (2010)
Mild Renal Impairment and the Efficacy and Safety of Liraglutide
Jaime Davidson et al.
Endocrine Practice (2010)
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients
Andreas Holstein et al.
EXPERT OPINION ON DRUG SAFETY (2010)
Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis
Masanori Abe et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis
Masanori Abe et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Review: Metformin: Potential benefits and use in chronic kidney disease
Helen L. Pilmore
NEPHROLOGY (2010)
Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
Alfonso Lopez-Ruiz et al.
PHARMACY WORLD & SCIENCE (2010)
Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease
James B. Reilly et al.
SEMINARS IN DIALYSIS (2010)
Pharmacologic Management of the Older Patient With Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY (2009)
Metformin use in renal dysfunction: Is a serum creatinine threshold appropriate?
Ann M. Philbrick et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Diabetes Mellitus and CKD Awareness: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES)
Adam Whaley-Connell et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
Lisbeth V. Jacobsen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease
Maureen F. Moen et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin
M. V. Tzvetkov et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Antidiabetic Medication Use and Prevalence of Chronic Kidney Disease Among Patients With Type 2 Diabetes Mellitus in the United States
Carol E. Koro et al.
CLINICAL THERAPEUTICS (2009)
Exenatide-Associated Ischemic Renal Failure
W. J. Weise et al.
DIABETES CARE (2009)
Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients
Sylvia P. B. Ramirez et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes
Steven M. Brunelli et al.
KIDNEY INTERNATIONAL (2009)
Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?
Masakazu Haneda et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome
Juraporn Pongwecharak et al.
PHARMACY WORLD & SCIENCE (2009)
Management of Diabetes in Patients with Chronic Kidney Disease
Ziauddin Ahmed et al.
POSTGRADUATE MEDICINE (2009)
Plasma Concentration of Pioglitazone in Patients With Type 2 Diabetes on Hemodialysis
Masanori Abe et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2009)
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan et al.
DIABETES OBESITY & METABOLISM (2008)
Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients
P. Aramwit et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2008)
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease
Christian A. Schneider et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Paget's disease of the mandible
Mayank B. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Medications in the kidney
A. J. Scheen
ACTA CLINICA BELGICA (2008)
Management of glycemia in patients with diabetes mellitus and CKD
Noah D. Lubowsky et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Effect of renal impairment on the pharmacokinetics of exenatide
Helle Linnebjerg et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
Arthur J. Bergman et al.
DIABETES CARE (2007)
Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection - Effectiveness and side effects
Chih-Kang Chiang et al.
DIABETES CARE (2007)
Thiazolidinedi ones and their fluid-related adverse effects - Facts, fiction and putative management strategies
Janaka Karalliedde et al.
DRUG SAFETY (2007)
Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2007)
Protection of the kidney by thiazolidinediones: An assessment from bench to bedside
P. A. Sarafidis et al.
KIDNEY INTERNATIONAL (2006)
Peroxisome proliferator-activated receptor gamma agonists in renal disease
Pedro Iglesias et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus
A Ersoy et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Contraindications can damage your health - is metformin a case in point?
A Holstein et al.
DIABETOLOGIA (2005)
Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment
G Holmes et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis
TYH Wong et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Renal status among patients using metformin in a primary care setting
L Kennedy et al.
DIABETES CARE (2005)
Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease
RW Snyder et al.
SEMINARS IN DIALYSIS (2004)
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
G Schernthaner et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Gliclazide modified release*: results of a 2-year study in patients with type 2 diabetes
P Drouin et al.
DIABETES OBESITY & METABOLISM (2004)
Clinical pharmacokinetics of nateglinide - A rapidly-absorbed, short-acting insulinotropic agent
JF McLeod
CLINICAL PHARMACOKINETICS (2004)
Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: A post hoc analysis
A Agrawal et al.
CLINICAL THERAPEUTICS (2003)
Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients
G Biesenbach et al.
DIABETIC MEDICINE (2003)
Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis
HJ Manley et al.
PHARMACOTHERAPY (2003)
The pharmacokinetics of pioglitazone in patients with impaired renal function
K Budde et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure
T Nagai et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2003)
Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function
C Hasslacher
DIABETES CARE (2003)
Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency
MC Chapelsky et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Pharmacokinetics of nateglinide in renally impaired diabetic patients
D Devineni et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Pharmacokinetics of rosiglitazone in patients with end-stage renal disease
K Thompson-Culkin et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2002)
Leptin and renal disease
G Wolf et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2002)
Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide
A Holstein et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2001)
Contraindications to metformin therapy in patients with Type 2 diabetes - a population-based study of adherence to prescribing guidelines
AM Emslie-Smith et al.
DIABETIC MEDICINE (2001)
Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment
S Schumacher et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients
K Rave et al.
DIABETES CARE (2001)
Pharmacokinetics of repaglinide in subjects with renal impairment
TC Marbury et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease
J Krepinsky et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2000)
Miglitol - A review of its therapeutic potential in type 2 diabetes mellitus
LJ Scott et al.
DRUGS (2000)
分享论文
